NO974727D0 - Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation - Google Patents

Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation

Info

Publication number
NO974727D0
NO974727D0 NO974727A NO974727A NO974727D0 NO 974727 D0 NO974727 D0 NO 974727D0 NO 974727 A NO974727 A NO 974727A NO 974727 A NO974727 A NO 974727A NO 974727 D0 NO974727 D0 NO 974727D0
Authority
NO
Norway
Prior art keywords
immunostimulatory
immunogenic
preparation
methods
oligosaccharide compositions
Prior art date
Application number
NO974727A
Other languages
Norwegian (no)
Other versions
NO974727L (en
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Publication of NO974727D0 publication Critical patent/NO974727D0/en
Publication of NO974727L publication Critical patent/NO974727L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO974727A 1995-06-07 1997-10-13 Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation NO974727L (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
PCT/CA1996/000387 WO1996040225A1 (en) 1995-06-07 1996-06-06 Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them

Publications (2)

Publication Number Publication Date
NO974727D0 true NO974727D0 (en) 1997-10-13
NO974727L NO974727L (en) 1997-12-08

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974727A NO974727L (en) 1995-06-07 1997-10-13 Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation

Country Status (10)

Country Link
EP (1) EP0831894A1 (en)
JP (1) JPH11506110A (en)
KR (1) KR19990007777A (en)
AU (1) AU725279B2 (en)
CZ (1) CZ327897A3 (en)
IL (1) IL121585A0 (en)
MX (1) MX9707944A (en)
NO (1) NO974727L (en)
NZ (1) NZ309713A (en)
WO (1) WO1996040225A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69708318T3 (en) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville NEISSERIA MENINGITIDIS SEROGRUPPE B GLYCOCONJUGATES AND METHOD FOR THEIR USE
KR20010021953A (en) * 1997-07-17 2001-03-15 추후제출 Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
EP1073667A2 (en) 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
NZ553554A (en) * 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
RU2531234C2 (en) * 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи POLYSACCHARIDE-PROTEIN CONJUGATE POLYSACCHARIDE-PROTEIN FOR INDUCING IMMUNE RESPONSE AND PROTECTION AGAINST Staphylococcus aureus INFECTION, METHODS OF CONJUGATE OBTAINING (VERSIONS), CONJUGATE-CONTAINING COMPOSITION AND METHODS OF INDUCING IMMUNE RESPONSE AND PREVENTION OF Staphylococcus aureus INFECTION
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3096785B1 (en) * 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN106879257B (en) * 2014-09-26 2020-08-11 马普科技促进协会 Vaccine against Streptococcus pneumoniae (Streptococcus pneumoniae) serotype 8
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EA039427B1 (en) 2016-08-05 2022-01-26 Санофи Пастер Инк. Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3678694A4 (en) * 2017-09-07 2021-10-20 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
IL304977A (en) 2018-02-05 2023-10-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11147864B2 (en) 2018-02-05 2021-10-19 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20190121713A (en) 2018-04-18 2019-10-28 에스케이바이오사이언스(주) Capsular saccharide of Streptococcus pneumoniae and the immunogenic conjugates thereof
JP2022512345A (en) * 2018-12-12 2022-02-03 ファイザー・インク Immunogenic Multiple Heteroantigen Polysaccharide-Protein Conjugates and Their Use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (en) * 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DK0567452T3 (en) * 1990-12-18 1996-10-14 Univ Washington Dialysate production system with dialysate pellets
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
AU725279B2 (en) 2000-10-12
JPH11506110A (en) 1999-06-02
MX9707944A (en) 1998-06-30
AU5994496A (en) 1996-12-30
CZ327897A3 (en) 1998-02-18
KR19990007777A (en) 1999-01-25
EP0831894A1 (en) 1998-04-01
NO974727L (en) 1997-12-08
WO1996040225A1 (en) 1996-12-19
IL121585A0 (en) 1998-02-08
NZ309713A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
NO974727D0 (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation
NO976072L (en) Propiophenone derivatives and process for their preparation
ZA961460B (en) Vaccine compositions
DK0909327T3 (en) Erythromycins and Methods for their Preparation
EE9500064A (en) Substituted 1H-imidazoles, methods for their preparation, and pharmaceutical compositions
AU2971395A (en) Ceramic products, methods for their preparation, and glazing formulations for such products
PL317071A1 (en) Novel derivatives of erythromycin, method of obtaining them and their application as medical agents
NO975490L (en) Heliobacter pylori antigens and vaccine compositions
DK0832104T3 (en) Dolastatin derivatives, their preparation and use
ZA964054B (en) Immunostimulating wound healing compositions and methods for preparing and using same.
AU6118096A (en) Immunogenic and immunostimulatory oligosaccharide compositio ns and methods of making and using them
NO970293D0 (en) Substituted camptothecin derivatives and process for its preparation
NO982329D0 (en) Cancer vaccine and method of preparation thereof
NO893196D0 (en) HYBRID-PROTEIN-C COMPOSITIONS AND PROCEDURES FOR THEIR PREPARATION.
NZ240369A (en) Muramyl dipeptide derivatives and vaccine compositions
DK0735042T3 (en) Maltitol composition and process for its preparation
GB9401787D0 (en) Vaccine compositions
HUT75112A (en) Oxathiolanes, method for their preparation and pharmaceutical compositions contating same
PL311838A1 (en) Novel derivatives of thienopyridone, method of obtaining them as well as pharmaceutical preparation and method of obtaining same
AP9901513A0 (en) Novel erythromycin derivatives method for preparing them and their use as medicine
NO915066D0 (en) CITRATE TESTER COMPOSITIONS AND PROCEDURES FOR THEIR PREPARATION
DK0994903T3 (en) Compositions containing galactosylated glycoproteins and methods for their preparation
ZA955409B (en) Keratolytic-wound healing compositions and methods for preparing and using same
ZA964016B (en) Bacterial antigens and vaccine compositions
NO973261L (en) Process and pharmaceutical compositions utilizing desmethylselegiline

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application